Kidney Research and Clinical Practice, Год журнала: 2023, Номер 42(4), С. 412 - 414
Опубликована: Июль 14, 2023
See the article "Genetic variations in HMGCR and PCSK9 kidney function: a Mendelian randomization study".
Язык: Английский
Diabetes & Metabolism Journal, Год журнала: 2025, Номер 49(1), С. 24 - 33
Опубликована: Янв. 1, 2025
This study aimed to investigate the prevalence, management, and comorbidities of diabetes mellitus among Korean adults. Data from Korea National Health Nutrition Examination Survey (2019-2022) were analyzed assess treatment, risk factors, diabetes. Comparisons between young older adults with emphasized. Among aged ≥30 years, prevalence is 15.5% during 2021-2022. Of these, 74.7% aware their condition, 70.9% received antidiabetic only 32.4% achieved glycosylated hemoglobin (HbA1c) <6.5%. Moreover, 15.9% met integrated management targets, which included HbA1c <6.5%, blood pressure <140/85 mm Hg, low-density lipoprotein cholesterol <100 mg/dL. In 19 39 was 2.2%. them, 43.3% 34.6% 29.6% Obesity affected 87.1%, 26.9% had both hypertension hypercholesterolemia. ≥65 29.3%, awareness, control rates 78.8%, 75.7%, 31.2%, respectively. Integrated targets (HbA1c <7.5%, hypertension, lipids) by 40.1%. Diabetes remains highly prevalent adults, significant gaps in glycemic, pressure, lipid control. Older show higher awareness treatment but limited outcomes. Young bear a burden obesity comorbidities, alongside low rates. Therefore, early intervention programs, education, strategies tailored younger populations are urgently required.
Язык: Английский
Процитировано
9
Diabetes & Metabolism Journal, Год журнала: 2024, Номер 48(3), С. 463 - 472
Опубликована: Март 19, 2024
Background: To investigate the prevalence, incidence, comorbidities, and management status of diabetic kidney disease (DKD) diabetes-related end-stage (ESKD) in South Korea.Methods: We used Korea National Health Nutrition Examination Survey data (2019 to 2021, <i>n</i>=2,665) for evaluation control rate glycemia comorbidities DKD, Korean Insurance Service-customized database (2008 2019, <i>n</i>=3,950,857) trends incidence prevalence ESKD, renin-angiotensin system (RAS) blockers sodium glucose cotransporter 2 (SGLT2) inhibitors use risk atherosclerotic cardiovascular (ASCVD) mortality according DKD stages. was defined as albuminuria or low estimated glomerular filtration (eGFR) <60 mL/min/1.73 m<sup>2</sup> patients with diabetes mellitus.Results: The 25.4% (albuminuria, 22.0%; eGFR, 6.73%) mellitus aged ≥30 years. Patients had a higher including hypertension, dyslipidemia, central obesity; however, their rates were lower than those without DKD. Prescription SGLT2 reduced eGFR increased steadily, reaching 5.94% 2019. Approximately 70% treated RAS blockers. diabetesrelated ESKD has been steadily increasing, older adults. ASCVD significantly associated an increase stage.Conclusion: is prevalent among independent factor morbidity mortality, which requiring intensive comorbidities. especially adults, during past decade.
Язык: Английский
Процитировано
9
Diabetes Research and Clinical Practice, Год журнала: 2024, Номер 208, С. 111109 - 111109
Опубликована: Янв. 21, 2024
Язык: Английский
Процитировано
4
Journal of Lipid and Atherosclerosis, Год журнала: 2025, Номер 14(1), С. 1 - 1
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Diabetes & Metabolism Journal, Год журнала: 2025, Номер 49(2), С. 172 - 182
Опубликована: Март 1, 2025
Background: This study aimed to examine trends in the prevalence, incidence, metabolic characteristics, and management of type 2 diabetes mellitus (T2DM) among young adults South Korea.Methods: Young with T2DM were defined as individuals aged 19 39 years who met diagnostic criteria for T2DM. Data from Korean National Health Insurance Service-Customized Database (2010–2020, <i>n</i>=225,497–372,726) analyzed evaluate profiles, comorbidities, antidiabetic drug prescription. Additional analyses performed using Korea Nutrition Examination Survey.Results: The prevalence significantly increased 1.02% 2010 2.02% 2020 (<i>P</i><0.001), corresponding 372,726 patients 2020. Over same period, incidence rate remained stable within range 0.36% 0.45%. Prediabetes steadily 15.53% 20.92%, affecting 3.87 million proportion obese also increased, 67.8% having a body mass index (BMI) ≥25 kg/m² 31.6% BMI ≥30 hypertension, dyslipidemia, fatty liver disease reaching 34.2%, 79.8%, 78.9%, respectively, Although overall pharmacological treatment low, prescription medications weight-reducing properties over period.Conclusion: nearly doubled past decade. strong association obesity comorbidities emphasizes urgent need targeted prevention strategies tailored this population.
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2025, Номер 17(7), С. 1117 - 1117
Опубликована: Март 26, 2025
Cancer survivors increasingly face cardiovascular disease (CVD), with diabetes as a major risk factor. This study investigates the relationship between adherence to antidiabetic medications and (CV) outcomes in cancer patients. Using data from Korean National Health Insurance Service-National Sample Cohort, we assessed clinical of adult patients prescribed medications. The population was categorized based on medication adherence, determined by possession ratio (MPR): good (MPR ≥ 0.8), moderate (0.5 ≤ MPR < poor 0.5) adherence. primary included overall CV mortality, secondary encompassing hospitalization for CVDs healthcare costs. Among 7928 diabetes, 59.7% were nonadherent (22.1% 37.6% adherence). Over median follow-up 5.7 years, 1462 deaths 2897 events confirmed. Multivariable adjusted analyses showed 1.70-fold 2.11-fold higher mortality groups, respectively, compared group. For associated 1.51-fold risk, 2.10-fold risk. new-onset increased 1.32-fold group 1.44-fold also significantly lower total costs nonadherence present underscores importance patients, revealing significant associations decreased events,
Язык: Английский
Процитировано
0
Yonsei Medical Journal, Год журнала: 2023, Номер 65(1), С. 19 - 19
Опубликована: Дек. 20, 2023
There are few studies in the literature on dosage of statin that equivalently reduces low-density lipoprotein cholesterol (LDL-C) compared to an ezetimibe combination and whether such regimens have differences safety. We lipid-modifying efficacy safety 5 mg rosuvastatin/10 those 20 rosuvastatin.
Язык: Английский
Процитировано
7
Nutrients, Год журнала: 2024, Номер 16(8), С. 1190 - 1190
Опубликована: Апрель 17, 2024
This study aimed to determine whether patients with type 2 diabetes can benefit from a meal plan designed based on management guidelines improve blood glucose levels. Participants were divided into intervention and control groups. The group consumed diabetic diet for weeks, while the their normal diet. After groups switched dietary regimens. participants’ demographic clinical characteristics evaluated, including factors such as pressure, lipid levels, weight waist circumference, levels (self-monitored continuously monitored), nutritional status, blood-based markers of nutrient intake. improved body fat percentage, low-density lipoprotein cholesterol, triglyceride glucose. energy composition ratio carbohydrates proteins changed favorably, sugar intake decreased. In addition, proportion continuous monitoring readings within range 180–250 mg/dL was relatively lower in than that group. Meals factors, stable daily life, significantly decrease carbohydrate ratio, increase protein ratio. help role interventions outcomes.
Язык: Английский
Процитировано
2
Diabetes & Metabolism Journal, Год журнала: 2024, Номер 48(1), С. 55 - 58
Опубликована: Янв. 30, 2024
Язык: Английский
Процитировано
1
Metabolites, Год журнала: 2024, Номер 14(3), С. 169 - 169
Опубликована: Март 18, 2024
Traditional lipid parameters—including total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-C), high-density (HDL-C), and non-HDL-C (calculated as TC minus HDL-C)—have long been used indicators of cardiovascular disease (CVD) risk. The laboratory records 9604 Korean adults who underwent traditional panel tests (TC, TG, HDL), well ApoB testing, were analyzed to evaluate the prevalence dyslipidemia high CVD risk (utilizing NCEP ATP III criteria for panels various test cutoffs recommended by international guidelines (145 mg/dL, 130 100 mg/dL)). overall dyslipidemia, determined criteria, was 27.4%. Utilizing 145 mg/dL resulted in figures 5.3%, 11.0%, 36.3%, respectively. concordance classification between at 78.4%, 81.3%, 74.7%, Up 17.5% participants, based on an cutoff ≥100 exhibited isolated absence anomalies. Incorporating testing could enhance identification Koreans
Язык: Английский
Процитировано
1